Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors

British Journal of Dermatology

Volumn 176, Issue 6, 2017, Pages 1649-1652

  Zarbo, A ^a   Belum, V R ^b   Sibaud, V ^c   Oudard, S ^d   Postow, M A ^e   Hsieh, J J ^b   Motzer, R J ^b   Busam, K J ^b   Lacouture, M E ^b  

^a HENRY FORD HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Institut Universitaire du Cancer   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOTIN; CLOBETASOL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 RECEPTOR INHIBITOR; HEMOGLOBIN; INFLIXIMAB; MANGANESE; PD 1 RECEPTOR INHIBITOR; SILICIC ACID; STEROID; THYROXINE; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; CD274 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ALOPECIA; ALOPECIA AREATA; ALOPECIA UNIVERSALIS; ANEMIA; ARTICLE; CANCER PATIENT; CASE REPORT; COLITIS; DIABETES MELLITUS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HAIR GROWTH; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; HYPERVITAMINOSIS; IMMUNOTHERAPY; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MALE; MANGANESE BLOOD LEVEL; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAIL DYSTROPHY; ONYCHOLYSIS; PANCREAS METASTASIS; PRIORITY JOURNAL; PRURITUS; RASH; SKIN BIOPSY; STEROID THERAPY; THYROXINE BLOOD LEVEL; TOPICAL TREATMENT; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; KIDNEY TUMOR; MELANOMA; METASTASIS; RENAL CELL CARCINOMA; SKIN TUMOR;

ADULT; AGED; ALOPECIA AREATA; ANTIBODIES, MONOCLONAL, HUMANIZED; B7-H1 ANTIGEN; CARCINOMA, RENAL CELL; CTLA-4 ANTIGEN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS;

EID: 85018823806     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15237     Document Type: Article

References (15)

1. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375–91.
2. Sibaud V, Meyer N, Lamant L. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016; 28:254–63.
3. Naidoo J, Schindler K, Querfeld C et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 2016; 4:383–9.
4. Belum VR, Benhuri B, Postow MA et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60:12–25.
5. Jaber SH, Cowen EW, Haworth LR et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol 2006; 142:166–72.
6. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443–54.
7. Assi H, Wilson KS. Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases. Curr Oncol 2013; 20:e165–9.
8. Hofmann L, Forschner A, Loquai C et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60:190–209.
9. Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med 2012; 366:1515–25.
10. Bene J, Moulis G, Auffret M et al. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. Rheumatology (Oxford) 2014; 53:1465–9.
11. Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol 2003; 139:1555–9.
12. Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med 1993; 66:541–4.
13. Lu W, Shapiro J, Yu M, Barekatain A et al. Alopecia areata: pathogenesis and potential for therapy. Expert Rev Mol Med 2006; 8:1–19.
14. Wang X, Marr AK, Breitkopf T et al. Hair follicle mesenchyme-associated PD-L1 regulates T-cell activation induced apoptosis: a potential mechanism of immune privilege. J Invest Dermatol 2014; 134:736–45.
15. Gilhar A, Landau M, Assy B et al. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J Invest Dermatol 2001; 117:1357–62.